The Financial Times, a business news organisation, completed the acquisition of Endpoints News, a source of news and analysis for the thriving biopharmaceutical industry. Financial terms were not disclosed. “We’re thrilled to invest in Endpoints, a fast-growing business with a robust reputation for delivering quality news to audiences across the biopharma ecosystem. There is strong alignment between Endpoints and the FT in terms of mission, business model and focus on reader revenues. This acquisition also supports our ambitions to reach new audiences in innovative sectors and grow our footprint in the US,” John Ridding, FT CEO.